
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc. exhibited a robust financial performance, with total revenue increasing by 84.7% year-over-year, supported by a significant 117.2% growth in Genomics revenue, which reached $252.9 million. The company is likely to realize higher average selling prices (ASPs) from its xF liquid biopsy assay and xT CDx test, contributing to improved margins and overall revenue from its oncology testing services. Additionally, Tempus anticipates growth through the potential for new pharmaceutical contracts and upcoming reimbursement for its minimal residual disease (MRD) testing, further strengthening its financial outlook.
Bears say
Tempus AI Inc. is experiencing a concerning decline in gross margins, with a drop from 76.8% in Q3 of the previous year to 69.7% in the current period, raising concerns about the company's profitability. The company faces significant risks, including competition, regulatory challenges, and difficulties in acquiring or retaining partnerships, which may further impede its ability to achieve sustainable profitability amid continued operating losses. Despite reporting revenue of $334.2 million that exceeded expectations, the substantial decrease in operating cash flow and the presence of debt on its balance sheet underscore the financial instability that could negatively impact its future growth prospects.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares